null James Brophy, MD, PhD

Senior Scientist, RI-MUHC , 5252 de Maisonneuve

Cardiovascular Health Across the Lifespan Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine, McGill University

Department of Medicine, Division of Cardiology, MUHC



risk assessment • Bayesian analysis • pharmacoepidemiology

Research Focus

My research focuses on cardiovascular epidemiology and includes pharmacoepidemiology, systematic reviews, cost-effectiveness analyses and health technology assessments.

Selected Publications

Click on Pubmed to see my current publications list

  • Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Brophy JM, Joseph L, Rouleau JL. Ann Intern Med. 2001 Apr 3;134(7):550-60. DOI: 10.7326/0003-4819-134-7-200104030-00008. PMID: 11281737.

  • Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.Lee TC, Cavalcanti RB, McDonald EG, Pilote L, Brophy JM. Am J Med. 2018 Oct;131(10):1228-1233.e1. doi: 10.1016/j.amjmed.2018.05.022. Epub 2018 Jun 12.

  • Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.Bally M, Beauchamp ME, Abrahamowicz M, Nadeau L, Brophy JM. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):69-77. doi: 10.1002/pds.4358. Epub 2017 Nov 24.

  • Variability in High-Sensitivity Cardiac Troponin T Testing in Stable Patients With and Without Coronary Artery Disease. Brophy JM, Dagenais GR, Boyer L, Garcia-Labbé D, Bogaty P. Can J Cardiol. 2019 Nov;35(11):1505-1512. doi: 10.1016/j.cjca.2019.08.022. Epub 2019 Aug 22. DOI:10.1016/j.cjca.2019.08.022. PMID: 31679620.

  • Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.Etminan M, Sodhi M, Ganjizadeh-Zavareh S, Carleton B, Kezouh A, Brophy JM. J Am Coll Cardiol. 2019 Sep 17;74(11):1444-1450. doi: 10.1016/j.jacc.2019.07.035. DOI: 10.1016/j.jacc.2019.07.035. PMID: 31514945.